These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 22559284)

  • 1. FGFR3 targeting strategies for achondroplasia.
    Laederich MB; Horton WA
    Expert Rev Mol Med; 2012 Jan; 14():e11. PubMed ID: 22559284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of PPADS on achondroplasic chondrocytes: inhibition of FGF receptor type 3 over-activity.
    Guzmán-Aránguez A; Crooke A; Yayon A; Pintor J
    Eur J Pharmacol; 2008 Apr; 584(1):72-7. PubMed ID: 18336810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Achondroplasia: pathogenesis and implications for future treatment.
    Laederich MB; Horton WA
    Curr Opin Pediatr; 2010 Aug; 22(4):516-23. PubMed ID: 20601886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cytokines in bone diseases. FGF receptor signaling and achondroplasia/hypochondroplasia].
    Tanaka H
    Clin Calcium; 2010 Oct; 20(10):1490-6. PubMed ID: 20890030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane domain point mutation found in achondroplasia.
    Webster MK; Donoghue DJ
    EMBO J; 1996 Feb; 15(3):520-7. PubMed ID: 8599935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant FGFR3 associated with SADDAN disease causes cytoskeleton disorganization through PLCγ1/Src-mediated paxillin hyperphosphorylation.
    Montone R; Romanelli MG; Baruzzi A; Ferrarini F; Liboi E; Lievens PM
    Int J Biochem Cell Biol; 2018 Feb; 95():17-26. PubMed ID: 29242050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3.
    Colvin JS; Bohne BA; Harding GW; McEwen DG; Ornitz DM
    Nat Genet; 1996 Apr; 12(4):390-7. PubMed ID: 8630492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The achondroplasia mutation does not alter the dimerization energetics of the fibroblast growth factor receptor 3 transmembrane domain.
    You M; Li E; Hristova K
    Biochemistry; 2006 May; 45(17):5551-6. PubMed ID: 16634636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGFR3 heterodimerization in achondroplasia, the most common form of human dwarfism.
    He L; Shobnam N; Wimley WC; Hristova K
    J Biol Chem; 2011 Apr; 286(15):13272-81. PubMed ID: 21324899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of the G375C and G346E achondroplasia mutations on FGFR3 activation.
    He L; Serrano C; Niphadkar N; Shobnam N; Hristova K
    PLoS One; 2012; 7(4):e34808. PubMed ID: 22529939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced binding of FGF1 to mutant fibroblast growth factor receptor 3.
    Khnykin D; Olsnes S
    Growth Factors; 2006 Jun; 24(2):111-9. PubMed ID: 16801131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo characterization of Recifercept, a soluble fibroblast growth factor receptor 3, as treatment for achondroplasia.
    Gonçalves D; Rignol G; Dellugat P; Hartmann G; Sarrazy Garcia S; Stavenhagen J; Santarelli L; Gouze E; Czech C
    PLoS One; 2020; 15(12):e0244368. PubMed ID: 33370388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel tyrosine kinase inhibitor restores chondrocyte differentiation and promotes bone growth in a gain-of-function Fgfr3 mouse model.
    Jonquoy A; Mugniery E; Benoist-Lasselin C; Kaci N; Le Corre L; Barbault F; Girard AL; Le Merrer Y; Busca P; Schibler L; Munnich A; Legeai-Mallet L
    Hum Mol Genet; 2012 Feb; 21(4):841-51. PubMed ID: 22072392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Fibroblast growth factor receptor and achondroplasia].
    Tanaka H
    Clin Calcium; 2006 Nov; 16(11):1888-93. PubMed ID: 17079857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization.
    Adar R; Monsonego-Ornan E; David P; Yayon A
    J Bone Miner Res; 2002 May; 17(5):860-8. PubMed ID: 12009017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and Achondroplasia.
    Hudkins RL; Allen E; Balcer A; Hoffman ID; Iyer S; Neal M; Nelson KJ; Rideout M; Ye Q; Starrett JH; Patel P; Harris T; Swanson RV; Bensen DC
    J Med Chem; 2024 Sep; 67(18):16737-16756. PubMed ID: 39258897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed bone age due to a dual effect of FGFR3 mutation in Achondroplasia.
    Pannier S; Mugniery E; Jonquoy A; Benoist-Lasselin C; Odent T; Jais JP; Munnich A; Legeai-Mallet L
    Bone; 2010 Nov; 47(5):905-15. PubMed ID: 20673820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia.
    Naski MC; Wang Q; Xu J; Ornitz DM
    Nat Genet; 1996 Jun; 13(2):233-7. PubMed ID: 8640234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postnatal soluble FGFR3 therapy rescues achondroplasia symptoms and restores bone growth in mice.
    Garcia S; Dirat B; Tognacci T; Rochet N; Mouska X; Bonnafous S; Patouraux S; Tran A; Gual P; Le Marchand-Brustel Y; Gennero I; Gouze E
    Sci Transl Med; 2013 Sep; 5(203):203ra124. PubMed ID: 24048522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expanding horizons of achondroplasia treatment: current options and future developments.
    Fafilek B; Bosakova M; Krejci P
    Osteoarthritis Cartilage; 2022 Apr; 30(4):535-544. PubMed ID: 34864168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.